Bionor Pharma is a leading vaccine company, searching for breakthrough treatments for HIV and other deadly viruses.

Latest news

Hide mandatory notifications of trade

Bionor enters into romidepsin supply agreement enabling advancement of its HIV therapeutic vaccine with Vacc-4x into full scale clinical Phase II

Financial .2015

(Oslo, Norway, 16 July 2015) Bionor Pharma ASA (Bionor) (OSE:BIONOR), a peptide vaccine company advancing a potential first therapeutic vaccine towards a functional cure for HIV, has signed an agreement with Celgene Corporation (Celgene) securing a continued supply of romidepsin (Istodax®) for use in a planned multicenter clinical Phase II study of Bionor’s most advanced and proprietary vaccine, Vacc-4x, with romidepsin.

Share capital increase registered

Financial .2015

(Oslo, Norway, 23 June 2015) With reference to the announcement made on 18 June 2015 regarding issuance of shares to former employee Birger Sørensen under a share option agreement, the share capital increase has now been registered in the Companies Register.

Exercise of share options

Financial .2015

(Oslo, Norway, 18 June 2015) The Board of Directors of Bionor Pharma ASA (OSE:BIONOR) has resolved to issue 666,667 new shares in the Company based on options exercised by former employee Birger Sørensen.

Bionor enters into romidepsin supply agreement enabling advancement of its HIV therapeutic vaccine with Vacc-4x into full scale clinical Phase II

Financial .2015

(Oslo, Norway, 16 July 2015) Bionor Pharma ASA (Bionor) (OSE:BIONOR), a peptide vaccine company advancing a potential first therapeutic vaccine towards a functional cure for HIV, has signed an agreement with Celgene Corporation (Celgene) securing a continued supply of romidepsin (Istodax®) for use in a planned multicenter clinical Phase II study of Bionor’s most advanced and proprietary vaccine, Vacc-4x, with romidepsin.

Share capital increase registered

Financial .2015

(Oslo, Norway, 23 June 2015) With reference to the announcement made on 18 June 2015 regarding issuance of shares to former employee Birger Sørensen under a share option agreement, the share capital increase has now been registered in the Companies Register.

Bionor Pharma ASA issues shares to board members

Financial .2015

(Oslo, Norway, 23 June 2015) In accordance with the resolution by the Annual General Meeting of Bionor Pharma ASA (OSE: BIONOR) on 13 May 2015, all board members have been offered to subscribe shares in the Company valued at NOK 100,000 and the Chairman of the Board has been offered to subscribe shares valued at NOK 200,000.

Go to news section

Featured content